Item 5. Market for Registrant’s Common Equity
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
Market for Our Common Stock; Dividends
Our common stock began trading on the Nasdaq Global Select Market under the symbol “FLDM” on February 10, 2011.
We had 85 stockholders of record as of January 31, 2021; however, because many of our outstanding shares are held by brokers or other institutions on behalf of stockholders, we are unable to estimate the total number of beneficial owners represented by the holders of record.
We have never declared or paid cash dividends on our common stock and do not expect to pay dividends on our common stock for the foreseeable future. Instead, we anticipate that all of our earnings in the foreseeable future will be used for the operation and growth of our business.
Stock Performance Graph
The following performance graph shall not be deemed “soliciting material” or to be “filed” with the SEC for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any filing of Fluidigm Corporation under the Securities Act or the Exchange Act.
The following graph compares, from December 31, 2015 through December 31, 2020, the cumulative total return for our common stock, the Nasdaq Composite Total Return Index, and the Nasdaq US Benchmark Medical Equipment Index, assuming in each case an initial investment of $100 and reinvestment of all dividends. Such returns are based on historical results and are not intended to suggest future performance.
44
Sales of Unregistered Securities
None.
Issuer Purchases of Equity Securities
We did not repurchase any shares of our common stock during the year ended December 31, 2020.
ITEM 6. SELECTED FINANCIAL DATA
The following selected financial data should be read in conjunction with the consolidated financial statements and related notes thereto appearing elsewhere in this Form 10-K. We have derived the consolidated statement of operations data for the years ended December 31, 2020, 2019, and 2018, and consolidated balance sheet data as of December 31, 2020, and December 31, 2019 from audited consolidated financial statements included elsewhere in this Form 10-K. The consolidated statement of operations data for the years ended December 31, 2017, and 2016, and the consolidated balance sheet data as of December 31, 2018, December 31, 2017, and December 31, 2016 were derived from audited consolidated financial statements that are not included in this Form 10-K.
2020 2019 2018 2017 2016
(in thousands, except per share amounts)
Consolidated Statement of Operations Data:
Total revenue $ 138,144 $ 117,243 $ 112,964 $ 101,937 $ 104,446
Loss from operations (51,036) (51,839) (48,164) (58,360) (73,190)
Net loss (53,020) (64,790) (59,013) (60,535) (75,985)
Net loss per share, basic and diluted (0.74) (0.97) (1.49) (1.84) (2.62)
2020 2019 2018 2017 2016
(in thousands)
Consolidated Balance Sheet Data:
Cash, cash equivalents, and short and long-term investments $ 68,520 $ 58,639 $ 95,401 $ 63,136 $ 59,430
Working capital (1) 76,873 74,003 100,988 71,565 76,334
Total assets 324,757 264,812 303,647 287,351 306,395
Total long-term debt 54,224 53,821 172,058 195,238 194,951
Total stockholders’ equity 139,050 153,612 72,116 30,935 53,233
_________________________
(1) Working capital excludes deferred revenue.
45